PROAIR HFA medication for bronchial
July 1 2017 by Ray Sahelian, M.D.
PROAIR HFA (albuterol sulfate) Inhalation Aerosol is a relatively prescription medication selective beta2-adrenergic agonist indicated for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm in adults and children 12 years of age and older. Ivax Laboratories, Inc., a member of Teva Group, markets PROAIR HFA.
Clin Drug Investig. 2016. Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Albuterol (Salbuterol) Multi-dose Dry-Powder Inhaler and ProAir Hydrofluoroalkane for the Treatment of Persistent Asthma: Results of Two Randomized Double-Blind Studies. The bronchodilatory efficacy and pharmacokinetic/pharmacodynamic profiles of albuterol mDPI and ProAir HFA are comparable, with a safety profile consistent with that of inhaled albuterol.
PROAIR HFA Availability by prescription
PROAIR HFA is available as an 8.5-g canister that provides 200 actuations, with each actuation delivering 90 mcg of albuterol base from the actuator mouthpiece.
J Aerosol Med Pulm Drug Deliv. 2012. ProAir(®) HFA
delivers warmer, lower-impact, longer-duration plumes containing higher fine
particle dose than Ventolin HFA.
PROAIR HFA dosage
The recommended dose of PROAIR HFA in treating acute episodes of bronchospasm or prevention of asthmatic symptoms is two inhalations repeated every 4 to 6 hours. In some patients one inhalation every 4 hours may be sufficient. The usual dose for the prevention of EIB is two inhalations 15 to 30 minutes before exercise.
PROAIR HFA side effect, safety
PROAIR HFA side events, occur at an incidence rate of 10 percent. These PROAIR HFA side effects include headache, asthma, bronchitis, and pharyngitis.
Inhaled albuterol sulfate can produce paradoxical bronchospasm that may be life threatening. It should be recognized that paradoxical bronchospasm, when associated with inhaled formulations, frequently occurs with the first use of a new canister. PROAIR HFA, as with all sympathomimetic amines, should be used with caution in patients with cardiovascular disorder (especially coronary insufficiency, cardiac arrhythmias, and hypertension), convulsive disorders, hyperthyroidism, and diabetes. Do not exceed the recommended dose. Fatalities have been reported in associating with excessive use of inhaled sympathomimetic drugs in patients with asthma. Potential drug interactions can occur with beta blockers, diuretics, digoxin, or monoamine oxidase inhibitors and tricyclic antidepressants.